Evidence map›Paper›PMID 41115883›Full record

ArticleNature communications2025

A pan-immunotherapy signature to predict intratumoral CD8

Munetomo Takahashi, Mikiya Tsunoda, Hiroyasu Aoki, Masaki Kurosu, Haru Ogiwara, Shigeyuki Shichino, David Bending, Shumpei Ishikawa, James E D Thaventhiran, Kouji Matsushima and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Spatiotemporal CD8Cancer science · 2026
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Munetomo Takahashi *Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR, UK. munetomo.takahashi@gmail.com.ORCID http://orcid.org/0009-0001-5133-6415
Mikiya Tsunoda *Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.ORCID http://orcid.org/0000-0003-2931-8250
Hiroyasu AokiDepartment of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masaki KurosuDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
Haru OgiwaraDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
Shigeyuki ShichinoDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.ORCID http://orcid.org/0000-0002-1683-2448
David BendingDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK.ORCID http://orcid.org/0000-0003-0071-1163
Shumpei IshikawaDepartment of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
James E D ThaventhiranMedical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR, UK.ORCID http://orcid.org/0000-0001-8616-074X
Kouji MatsushimaDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.ORCID http://orcid.org/0000-0003-1056-171X
Satoshi UehaDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan. ueha@rs.tus.ac.jp.ORCID http://orcid.org/0000-0002-3871-9921

Funding

Japan Agency for Medical Research and Development (AMED) JP22fk0310509Japan Society for the Promotion of Science London (JSPS London) 17929397
6 · The paper itself

Abstract

Effective cancer immunotherapy relies on the clonal proliferation and expansion of CD8

Indexed as

CD8-Positive T-LymphocytesImmunotherapyNeoplasmsAnimalsAntigens, CDCell Line, TumorCell ProliferationFemaleHumansLymphocyte Activation Gene 3 ProteinLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorSingle-Cell AnalysisTranscriptomeAntigens, CDLymphocyte Activation Gene 3 ProteinProgrammed Cell Death 1 Receptor

Identifiers

PMID41115883
PMCPMC12537911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.